Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Br J Clin Pharmacol ; 76(5): 668-79, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23432361

RESUMO

AIM: The disturbed circadian rhythm in haemodialysis patients results in perturbed sleep. Short term melatonin supplementation has alleviated these sleep problems. Our aim was to investigate the effects of long-term melatonin supplementation on quality of life and sleep. METHODS: In this randomized double-blind placebo-controlled trial haemodialysis patients suffering from subjective sleep problems received melatonin 3 mg day(-1) vs. placebo during 12 months. The primary endpoint quality of life parameter 'vitality' was measured with Medical Outcomes Study Short Form-36. Secondary outcomes were improvement of three sleep parameters measured by actigraphy and nighttime salivary melatonin concentrations. RESULTS: Sixty-seven patients were randomized. Forty-two patients completed the trial. With melatonin, no beneficial effect on vitality was seen. Other quality of life parameters showed both advantageous and disadvantageous effects of melatonin. Considering sleep, at 3 months sleep efficiency and actual sleep time had improved with melatonin compared with placebo on haemodialysis days (difference 7.6%, 95% CI 0.77, 14.4 and 49 min, 95% CI 2.1, 95.9, respectively). At 12 months none of the sleep parameters differed significantly from placebo. Melatonin salivary concentrations at 6 months had significantly increased in the melatonin group compared with the placebo group. CONCLUSIONS: The high drop-out rate limits the strength of our conclusions. However, although a previous study reported beneficial short term effects of melatonin on sleep in haemodialysis patients, in this long-term study the positive effects disappeared during follow up (6-12 months). Also the quality of life parameter, vitality, did not improve. Efforts should be made to elucidate the mechanism responsible for the loss of effect with chronic use.


Assuntos
Melatonina/uso terapêutico , Qualidade de Vida , Diálise Renal , Transtornos do Sono do Ritmo Circadiano/tratamento farmacológico , Actigrafia , Idoso , Antioxidantes/administração & dosagem , Antioxidantes/uso terapêutico , Suplementos Nutricionais , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Masculino , Melatonina/administração & dosagem , Pessoa de Meia-Idade , Saliva/química , Sono/efeitos dos fármacos , Transtornos do Sono do Ritmo Circadiano/etiologia , Fatores de Tempo
2.
FASEB J ; 15(13): 2536-8, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11641256

RESUMO

It has long been suspected that stress can cause hair loss, although convincing evidence of this has been unavailable. Here, we show that in mice sonic stress significantly increased the number of hair follicles containing apoptotic cells and inhibited intrafollicular keratinocyte proliferation in situ. Sonic stress also significantly increased the number of activated perifollicular macrophage clusters and the number of degranulated mast cells, whereas it down-regulated the number of intraepithelial gd T lymphocytes. These stress-induced immune changes could be mimicked by injection of the neuropeptide substance P in nonstressed mice and were abrogated by a selective substance P receptor antagonist in stressed mice. We conclude that stress can indeed inhibit hair growth in vivo, probably via a substance P-dependent activation of macrophages and/or mast cells in the context of a brain-hair follicle axis.


Assuntos
Encéfalo/fisiologia , Folículo Piloso/crescimento & desenvolvimento , Estimulação Acústica , Animais , Apoptose/efeitos dos fármacos , Degranulação Celular , Divisão Celular/efeitos dos fármacos , Citocinas/biossíntese , Folículo Piloso/química , Folículo Piloso/efeitos dos fármacos , Antígenos de Histocompatibilidade Classe II/biossíntese , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas , Indóis/farmacologia , Isoindóis , Queratinócitos/química , Queratinócitos/citologia , Queratinócitos/efeitos dos fármacos , Antígeno Ki-67/análise , Macrófagos/metabolismo , Macrófagos/patologia , Mastócitos/fisiologia , Camundongos , Receptores de Antígenos de Linfócitos T gama-delta/biossíntese , Pele/metabolismo , Pele/patologia , Estresse Fisiológico/fisiopatologia , Substância P/farmacologia , Linfócitos T/citologia , Linfócitos T/metabolismo , Regulação para Cima
3.
Ugeskr Laeger ; 162(15): 2195-8, 2000 Apr 10.
Artigo em Dinamarquês | MEDLINE | ID: mdl-10776066

RESUMO

Functional Electrical Stimulation (FES) is a controlled use of electrical stimulation of muscle contractions to obtain function. FES is utilised today in the treatment of spinal cord injured individuals for diaphragmatic pacing, bladder and bowel management, ejaculation, walking and hand function, as well as conditioning. We present The Freehand System, which consists of implanted electrodes to arm and hand muscles. This system has now been implanted in the first two Nordic tetraplegics. Candidates are tetraplegics with C5-6 lesions. After implantation it may take 6-8 months before the tetraplegic person can expect to use The Freehand System completely in daily life. The tetraplegic individual can choose between two grasps. The Freehand System can for some few very physically disabled tetraplegics be a good aid to increase their level of activities of daily living and independence. Continued development in the coming years may broaden the indications with benefit for more individuals.


Assuntos
Terapia por Estimulação Elétrica , Eletrodos Implantados , Força da Mão , Músculo Esquelético/fisiopatologia , Quadriplegia/reabilitação , Atividades Cotidianas , Terapia por Estimulação Elétrica/efeitos adversos , Terapia por Estimulação Elétrica/instrumentação , Terapia por Estimulação Elétrica/métodos , Humanos , Contração Muscular , Quadriplegia/fisiopatologia
4.
J Lipid Res ; 38(3): 503-15, 1997 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9101431

RESUMO

Dietary n-3 fatty acids (FAs) reduce postprandial triacylglycerol concentrations in humans by unknown mechanisms. Our goals were to reproduce this phenomenon in the rat, and then to determine the mechanism. In an oral fat tolerance study two groups of rats were fed diets containing 2.1% ethyl esters of n-3 FA or olive oil for 2 weeks. After gavaging with emulsified soybean oil, the postprandial chylomicron triacylglycerol levels in the n-3 FA group were reduced by 40% (P < 0.05). The hypothesis that n-3 FA feeding reduced chylomicron production/secretion from the gut was tested by blocking chylomicron removal with Triton WR1339 before gavaging the rats with the fat load. This completely eliminated the hypochylomicronemic effect suggesting that chylomicron input was not inhibited by n-3 FAs. Chylomicron clearance was studied by injecting chylomicrons containing radioactive retinyl esters and triacylglycerol into rats from both groups. Pre-feeding with n-3 FAs accelerated the removal of chylomicron triacylglycerol and retinyl esters from the plasma with significantly lower fractions of dose remaining at 2, 4, and 8 min post-injection for both tracers. These findings suggest than n-3 FAs reduce postprandial chylomicronemia in the rat by accelerating chylomicron lipid clearance.


Assuntos
Quilomícrons/metabolismo , Ácidos Graxos Ômega-3/farmacologia , Triglicerídeos/metabolismo , Animais , Peso Corporal , Quilomícrons/sangue , Simulação por Computador , Gorduras na Dieta/administração & dosagem , Gorduras na Dieta/farmacologia , Ácidos Graxos Ômega-3/administração & dosagem , Intestino Delgado/metabolismo , Linfa/química , Masculino , Modelos Biológicos , Tamanho da Partícula , Fosfolipídeos/metabolismo , Óleos de Plantas/química , Óleos de Plantas/metabolismo , Polietilenoglicóis/farmacologia , Ratos , Ratos Wistar , Tensoativos/farmacologia , Triglicerídeos/sangue , Vitamina A/análogos & derivados , Vitamina A/sangue , Vitamina A/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA